

ORIGINAL ARTICLE

Open Access



Clinical value of semi-quantitative parameters in ^{68}Ga -DOTANOC PET/CT in treatment and diagnostics of cranial meningioma in a single-center retrospective analysis

Friedrich Weitzer^{1*} , Susanne Stanzel¹, Elisabeth Plhak¹ and Reingard Maria Aigner¹

*Correspondence:
friedrich.weitzer@medunigraz.at

¹ Department of Radiology,
Division of Nuclear Medicine
Medical, University of Graz,
Auenbruggerplatz 9A, 8036 Graz,
Austria

Abstract

Background: The value of somatostatin-analogue PET tracers in theranostics in cranial meningioma has been demonstrated in several studies; however, the value of semi-quantitative parameters for therapy and patient outcome is still unclear.

Methods: A retrospective study was performed comparing measured semi-quantitative ^{68}Ga -DOTANOC PET/CT parameters (maximum standardized uptake value = SUVmax, mean standardized uptake value = SUVmean, and metabolic tumor volume = MTV) and calculated ratios (SUVmax tumor to pituitary gland and SUVmax tumor to superior sinus sagittalis), versus the WHO grades and overall outcome. Patients with histological confirmed meningioma or high probability for meningioma in the previous cranial MRI were eligible.

Results: Thirty-two patients from January 2018 to February 2023 were retrospectively included. The WHO grade I meningioma was confirmed in 17 patients, the WHO grade II in five patients, and the WHO grade III in two patients, while in eight patients, diagnosis was solely based on MRI and ^{68}Ga -DOTANOC PET/CT findings. In 12 cases, stable disease was present, in 15 cases, radiation therapy was chosen, in three cases, neurosurgery was preferred, while in two cases, palliative care was chosen. Median SUVmax values increased with the WHO grade (15.84, 17.22, and 28.4, $p=0.134$, Kruskal–Wallis test), and no statistically significant difference was present for MTV, SUVmax, and calculated ratios.

Conclusion: Increased SUVmax values in the tumor in ^{68}Ga -DOTANOC PET/CT are associated with higher WHO grade, although further studies including larger patient collectives are needed to solidify this hypothesis.

Keywords: ^{68}Ga -DOTANOC, Meningioma, Semi-quantitative parameters, PET/CT

Introduction

Meningiomas are the most common intracranial tumor, evolving from a mesodermal line. They account for approximately 13–26% of all central nervous tumors (Vernooij et al. 2007; Marosi et al. 2008). Although generally considered benign entities with a slow growth rate, they can show invasive growth and high recurrence rate. Meningiomas are divided into three histological sub-types according to the World Health Organization (WHO) classification: grade I: benign, grade II: atypical, and grade III: anaplastic or malignant. Recurrence rates increase from up to 25% for grade I to up to 94% for grade III. While 5-year survival rate for grade I exceeds 80%, it is poorer for malignant and atypical meningiomas at less than 60% (Marosi et al. 2008). Treatment is usually surgical when localized and radiotherapy in more widespread lesions, while peptide receptor radionuclide therapy (PRRT) could achieve stable disease in up to 66.6% (Filippi et al. 2022; Pirisino et al. 2022). Although seen as gold standard in grade III, radiotherapy is debated for grade II and generally not indicated for grade I when resectable (Maggio et al. 2021).

According to the current European Association of Neuro-Oncology (EANO) guideline (Goldbrunner et al. 2021), the diagnosis of intracranial meningioma can be based on MRI and CT scans with high probability in most cases. PET using somatostatin analogs can delineate meningiomas expressing somatostatin receptor 2, although this is not available as standard practice yet. Furthermore, for surgery guidance, PET images should be integrated especially for intraosseous meningioma. The most commonly used somatostatin analogs or somatostatin receptor (SSTR) ligands are [$^{68}\text{Ga-DOTA}^0\text{-Tyr}^3$] octreotide ($^{68}\text{Ga-DOTATOC}$), [$^{68}\text{Ga-DOTA}^0\text{-Tyr}^3$] octreotide ($^{68}\text{Ga-DOTATATE}$), and [$^{68}\text{Ga-DOTA}^0\text{-}^1\text{NaI}^3$] octreotide ($^{68}\text{Ga-DOTANOC}$). Gallium-68 has a physical half-life of 68 min and can be obtained from a Germanium-68/Gallium-68 generator system, enabling in-house production without the need for a cyclotron (Galldiks et al. 2017). Since SSTR ligands do not cross the blood/brain barrier, high contrast and excellent target-to-background contrast are provided, enhancing the diagnostic abilities of PET/CT.

Objective

To determine the value of semi-quantitative parameters in $^{68}\text{Ga-DOTANOC}$ PET/CT in intracranial meningiomas in a retrospective single-center study.

Patients and methods

This retrospective single-center study included patients undergoing $^{68}\text{Ga-DOTANOC}$ PET/CT scans at our division from January 2018 to February 2023 for the diagnosis of suspected intracranial meningioma or the restaging of remnant and/or recurrent meningioma. Patients from both sexes and from all ages were eligible.

The Gallium-68 labeled DOTANOC ligand was prepared in-house according to the established EANM guideline on current good radiopharmacy practice (cGRPP) (Aerts et al. 2014; Gillings et al. 2022). Gallium-68 was obtained from a Germanium-68/Gallium-68 generator (Galli Ad, IRE, Fleurus, Belgium). Quality control was successfully

carried out according to the European Pharmacopeia. All prepared products were apyrogenic and sterile with a radiochemical purity > 91%.

All PET/CT examinations were performed on three dedicated PET/CT systems in 3D mode (Discovery MI, GE Healthcare, Milwaukee, WI, USA; Discovery ST, GE Healthcare, Milwaukee, WI, USA; and Biograph mCT, Siemens, Erlangen, Germany); patients were unsystematically referred to each scanner. Target dose was 2 MBq kg body weight range 80–200 MBq according to established EANM dose recommendations (Jacobs et al. 2005).

Images of the skull were acquired over 10-min scan time 60 min after i.v. injection while additional images of the body stem from skull base to mid-thighs were acquired in selected cases by discontinuously craniocaudal bed movement and an acquisition time of 2 min per bed position afterwards. Transmission CT scans for attenuation correction were acquired using helical mode without the use of a contrast agent. Both PET and CT scans were reconstructed with a slice thickness of 3.75 mm. All studies were interpreted by two experienced Nuclear Medicine physicians in consensus reading.

⁶⁸Ga-DOTANOC positive tumor lesions were visually identified as focal uptake significantly higher than adjacent background activity, not associated with physiological uptake in the pituitary gland as recommend by the generally accepted international EANM/SNMMI criteria (Bozkurt et al. 2017). Volumes of interest (VOI) to acquire SUVmax, SUVmean, and MTV were manually drawn over pathological uptake in the tumor, avoiding the very high physiological activity in the pituitary gland. VOIs were also drawn to acquire SUVmax values in the pituitary gland (SUVpit) and superior sinus sagittalis (SUVsss) to obtain raw data for calculating the SUVmax ratio tumor/pituitary gland (SUVRpit) and SUVmax ratio tumor/superior sinus sagittalis (SUVRsss).

Image analysis and semi-quantitative data for both primary tumor and metastasis were acquired on the manufacturer supplied workstation (AW Server 3.2 Ext. 4.0, GE Healthcare, Milwaukee, WI, USA) using the manufacturer provided auto-snake tool with automatic threshold definition pre-set to 42% of SUVmax. The Kruskal–Wallis test was used to compare SUVmax, SUVmean, SUVRpit, SUVRsss, and MTV between the WHO grades in meningioma. Statistical examination was performed with IBM™ SPSS™ Statistics version 29.0 (Chicago, Ill, USA).

Results

From January 2018 to February 2023, 1309 ⁶⁸Ga-DOTANOC PET/CT examinations were performed at our division. The absolute and relative number of examinations increased over time. In 32/1309 selected cases (2.44%, 26 females), intracranial meningioma was already known or highly suspected (see Table 1 for patient characteristics and demographics).

The previous treatment was performed in 30 patients (81.1%), including neurosurgery and/or radiation therapy, while histologically proven meningioma was available in 25 patients (67.6%). Regarding the WHO histological classification, the WHO grade I was present in 17 cases (45.9%), the WHO grade II in 6 cases (16.2%), and the WHO grade III in only 2 cases (5.4%). In 12 cases (32.4%), stable disease was present, in 15 cases (40.5%), proton beam radiation therapy was chosen, in three cases (8.1%), neurosurgery was preferred, while in two cases (5.4%), palliative care was chosen due to multiple recurrent

Table 1 Patient characteristics including the previous treatment and the WHO histological classification of the intracranial meningioma

Analyzed parameters	Patients	Percentage
Female (%)	26/32	81.3%
Age (years)		
Mean	54.94	Range: 6–82 years
Median	58.34	
Standard deviation	15.38	
Body mass index		
Mean	26.51	Range: 17.8—40.4
Median	25.08	
Standard deviation	5.71	
Previous treatment		
Neurosurgery	17	45.9%
Neurosurgery and radiation therapy	7	18.9%
Radiation therapy	6	16.2%
None	7	18.9%
WHO histological classification		
Grade I	17	45.9%
Grade II	6	16.2%
Grade III	2	5.4%
MRI presumptive diagnosis	12	32.4%




Fig. 1 Flowchart of the included patients and therapy decisions based on PET/CT

intracranial lesions. All depicted meningiomas showed a significant ^{68}Ga -DOTANOC uptake with a median SUVmax value of 17.3 (range: 6.12–64.78), a median SUVmean of 8.4 (range: 1.78–24.06), and a median MTV of 4.89 cm^3 (range: 0.16–76.4 cm^3) (see Fig. 1 for graphic display).

Significant ^{68}Ga -DOTANOC uptake with a good contrast to the surrounding tissue and a sharply demarcated tumor border was present in all meningiomas, confirming the value of ^{68}Ga -DOTANOC PET/CT in the diagnosis of meningioma. No significant differences between visual appearance of tumor volume and extension and semi-automated acquisition of MTV were observed (see Fig. 2 for a representative case).

Analysis of semi-quantitative parameters, the main objective of this study, showed an increase in median SUVmax in the tumor associated with the WHO grade while no association was present for median MTV (15.84 in the WHO grade I, 17.22 in the WHO grade II, and 28.4 in the WHO grade III and 5.26, 3.23, and 18.59, respectively); however, no significance could be demonstrated ($p=0.134$ for SUVmax and $p=0.216$ for MTV). No statistical significance was present between ^{68}Ga -DOTANOC uptake using SUVmean values in the tumor and WHO grade ($p=0.180$), and for calculated tumor to superior sinus sagittalis ratio (median 6.24, 4.34, and 16.47; $p=0.067$), while the tumor-to-pituitary gland ratio did not differ (0.98, 1.10, and 0.95; $p=0.405$) (see Table 2).

Discussion

Diagnosis and determination of topographic extension of intracranial tumors is based on neuroimaging consisting mainly MRI and seldom cranial CT with or without contrast agent. However, these radiological modalities have limitations, especially when post-therapeutic changes are present (Galldiks et al. 2017). ^{68}Ga -DOTANOC PET/CT has the potential to present a meaningful alternative if the previous MRI findings are unclear as




Fig. 2 ^{68}Ga -DOTANOC PET/CT showing meningioma of the left olfactory nerve with intra- and extra-cranial tumor masses. Patient was a 64-year-old male neurosurgical treated before PET/CT. Stable disease and the WHO grade II allowed a “watch and wait” strategy. Arrow: physiological tracer uptake in the pituitary gland **a**: PET images and **b**: fused images in three planes

Table 2 Semi-quantitative parameters for different WHO grades

n = 24	SUVmax	SUVmean	MTV	SUVpit	SUVsss	SUVRpit	SUVRsss
<i>WHO grade I (n = 17)</i>							
Mean	16.45	8.35	11.74	15.76	2.36	1.09	7.36
Median	15.84	8.53	5.26	14.53	2.39	0.98	6.24
Standard deviation	7.69	4.05	17.25	5.60	0.58	0.42	3.75
Minimum	6.12	1.78	1.42	6.27	1.16	0.38	2.51
Maximum	38.68	19.96	76.04	27.14	3.18	2.03	16.15
<i>WHO grade II (n = 5)</i>							
Mean	18.57	8.00	6.76	13.21	3.55	1.87	5.97
Median	17.22	7.78	3.23	15.19	4.33	1.10	4.34
Standard deviation	5.13	1.49	5.69	5.19	1.21	1.51	2.87
Minimum	11.60	6.25	1.92	5.57	1.77	0.95	3.79
Maximum	27.18	10.02	16.45	18.45	4.69	4.88	11.33
<i>WHO grade III (n = 2)</i>							
Mean	28.42	10.44	18.59	29.87	1.71	0.95	16.47
Median	28.42	10.44	18.59	29.87	1.71	0.95	16.47
Standard deviation	5.29	0.19	4.54	1.28	0.15	0.14	1.65
Minimum	23.13	10.25	14.04	28.59	1.56	0.81	14.83
Maximum	33.70	10.63	23.13	31.14	1.86	1.08	18.12

SUVmax maximum standard uptake value in the tumor, *SUVmean* mean standard uptake value in the tumor, *MTV* metabolic tumor volume, *SUVpit* maximum standard uptake value in the pituitary gland, *SUVsss* maximum standard uptake value in the superior sinus sagittalis, *SUVRpit* tumor-to-pituitary gland ratio, and *SUVRsss* tumor-to-sinus sagittalis ratio

proven in a recently published systematic review (Filippi et al. 2022). Meningioma unlike other intracranial tumors has a high incidence of somatostatin receptors posing a potential target for both diagnosis and therapy (Dutour et al. 1998). Furthermore, a retrospective study by Milosevic et al. (Milosevic et al. 2023) showed no diagnostic improvement for detection and differentiation of meningioma using PET/MRI and a dedicated MRI protocol.

Before discussing the results concerning the meningiomas, it is noteworthy that a higher variability between the physiological tracer uptakes in the pituitary gland with a *SUVpit* (*SUVmax* values) ranging from minimum 5.57 to maximum 52.52 (median 18.19) than in the superior sinus sagittalis with a *SUVsss* (*SUVmax* values) ranging from minimum 0.94 to maximum 4.69 (median 2.37) was found. This finding is consistent to findings reported by Campos Neto et al. (2022) reporting a range from 12.75 to 32.03.

A similar approach to this topic was performed by Kim et al. (2022) evaluating semi-quantitative parameters in ⁶⁸Ga-DOTATATE PET/MRI in 166 meningiomas. Interestingly, in this study, the *SUVmax* values showed the highest sensitivity, while the *SUVRsss* values showed the highest specificity. The lack of reproducibility in our study may be caused by the smaller and possibly more heterogeneous patient collective.

Current guidelines including the 2017 EANM guideline for PET/CT imaging of neuroendocrine neoplasms (Bozkurt et al. 2017) mention the usability of radiolabeled somatostatin analogs for the diagnosis of meningioma without going into detail or describing the value of semi-quantitative parameters. No further amendments concerning this topic were made in a 2023 preprint SNMMI procedure standard/EANM practice guideline for SSTR receptor PET (Hope et al. 2023). A different and more concise approach is stated in the current EANO guideline (Goldbrunner et al. 2021)

on meningioma where the value of somatostatin receptor PET for distinguishing tumor from healthy tissue and postoperative tissue changes is mentioned; however, PET/CT is still not seen as standard practice due to the limited availability. Despite the recent advances in hybrid imaging and the widespread use of CT for attenuation correction, there are still pitfalls and limitation due to patient movement during the examination. Radiation exposure poses an additional limiting factor especially in children (Salmon et al. 2015).

The manufacturer supplied automatic set threshold of 42% of SUVmax proved adequate for tumor volume determination and MTV which is contradictory to the findings described by Kriwanek et al. (Kriwanek et al. 2022) examining the inter-observer variability of target delineation of meningioma where a threshold of 14% of SUVmax was deemed adequate. In the same study, a general increase in delineated tumor volume was present for most physicians, although a major drop was seen in one physician.

This small retrospective study has several limitations: First, the number of patients is limited, so a larger patient collective could produce more stable results. Secondly, a prospective setting comparing the same patient collective, and outcome would produce more valid data; however, this would be more time consuming especially regarding the individual patient outcome.

Conclusion

⁶⁸Ga-DOTANOC PET/CT plays a key role in the diagnosis and determination of the topographic extension in intracranial meningioma. Increased SUVmax and MTV values in the tumor in ⁶⁸Ga-DOTANOC PET/CT are associated with higher WHO grade. No correlation was present for calculated tumor to pituitary gland and tumor to superior sinus sagittalis ratios. Nevertheless, further studies including larger patient collectives are needed to solidify this hypothesis.

Author contributions

All contributing authors have contributed equivocally to the paper, read the paper, approved the contents, and meet the criteria for authorship as established. All the authors confirm that there is no conflict of interest—financial or otherwise—to declare. The authors believe that the article represents honest work, and can verify the validity of the results reported. This work or part of it has not been published in the current or a substantially similar form (in print or electronically, including websites), nor has been accepted for publication elsewhere, or is under consideration for publication in any other journal. There are no papers (published or under review), which duplicate parts of the work reported, or concern the same subjects as the present paper.

Funding

This paper has received no funds, grants, or other support from any funding source.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee (Ethikkommission der Medizinischen Universität Graz—Ethics Committee at Medical University of Graz (application number: 35-317 ex 22/23, approval date: July 7, 2023)). Being a retrospective study, the need for written informed consent was waived by the Ethics Committee at Medical University of Graz.

Consent for publication

All contributing authors have contributed equivocally to the paper, read the paper, approved the contents, and meet the criteria for authorship as established. All the authors confirm that there is no conflict of interest—financial or otherwise—to declare.

Consent to participate

Being a retrospective study, the need for written informed consent was waived by the Ethics Committee at Medical University of Graz.

Received: 5 January 2024 Accepted: 21 January 2024

Published online: 26 April 2024

References

- Aerts J, Ballinger JR, Behe M et al (2014) Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective. *J Label Comp Radiopharm* 57:615–620
- Bozkurt MF, Virgolini I, Balogova S et al (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with ⁶⁸Ga-DOTA-conjugated somatostatin receptor targeting peptides and ¹⁸F-DOPA. *Eur J Nucl Med Mol Imaging* 44:1588–1601
- Campos Neto GC, Amaro Junior E, Weltman E et al (2022) Comparative analysis of somatostatin analog uptake between successfully irradiated and non-irradiated meningiomas. *Einstein (sao Paulo)* 20:eAO0104
- Doutour A, Kumar U, Panetta R et al (1998) Expression of somatostatin receptor subtypes in human brain tumors. *Int J Cancer* 76:620–627
- Filippi L, Palumbo I, Bagni O et al (2022) Somatostatin receptor targeted PET-imaging for diagnosis, radiotherapy planning and theranostics of meningiomas: a systematic review of the literature. *Diagnostics* 12:1666
- Galldiks N, Albert NL, Sommerauer M et al (2017) PET imaging in patients with meningioma-report of the RANO/PET Group. *Neuro Oncol* 19:1576–1587
- Gillings N, Hjelstuen O, Behe M et al (2022) EANM guideline on quality risk management for radiopharmaceuticals. *Eur J Nucl Med Mol Imaging* 49:3353–3364
- Goldbrunner R, Stavrinou P, Jenkinson MD et al (2021) EANO guideline on the diagnosis and management of meningiomas. *Neuro Oncol* 23:1821–1834
- Hope TA, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald LK, Graham MM, Jacene HA, Heath CL, Mittra ES, Wright CL, Fendler WP, Herrmann K, Taieb D, Kjaer A (2023) SNMMI procedure standard/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors. *J Nucl Med* 64(2):204–210. <https://doi.org/10.2967/jnumed.122.264860>
- Jacobs F, Thierens H, Piepsz A et al (2005) Optimised tracer-dependent dosage cards to obtain weight-independent effective doses. *Eur J Nucl Med Mol Imaging* 32:581–588
- Kim SH, Roytman M, Madera G et al (2022) Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [⁶⁸Ga]-DOTATATE PET/MRI analysis in patients with meningioma. *Sci Rep* 12:9256
- Kriwanek F, Ulbrich L, Lechner W et al (2022) Impact of SSTR PET on inter-observer variability of target delineation of meningioma and the possibility of using threshold-based segmentations in radiation oncology. *Cancers (basel)* 14:4435
- Maggio I, Franceschi E, Tosoni A et al (2021) Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. *CNS Oncol* 10:CNS72
- Marosi C, Hassler M, Roessler K et al (2008) Meningioma. *Crit Rev Oncol Hematol* 67:153–171
- Milosevic A, Styczen H, Grueneisen J et al (2023) Evaluation of [⁶⁸Ga]-DOTATOC PET/MRI in patients with meningioma of the subcranial and intraorbital space. *J Nucl Med* 64:1185–1190
- Pirisino R, Filippi L, D'Agostini A et al (2022) Management of a patient with metastatic gastrointestinal neuroendocrine tumor and meningioma submitted to peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE. *Clin Nucl Med* 47:E692–E695
- Salmon E, Bernard Ir C, Hustinx R (2015) Pitfalls and limitations of PET/CT in brain imaging. In: Saunders, WB (ed) *Seminars in nuclear medicine*, pp 541–551
- Vernooij MW, Arfan Ikram M, Tanghe HL et al (2007) Incidental findings on brain MRI in the general population. *N Engl J Med* 357:1821–1828

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.